Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer
Thus, colored compounds are usually susceptible to photolytic degradation
a 5 mg/mL of each at a 1:1,000 dilution in buffer gives you approximately 1.76 M BPC-157 and 1.32 M TB-500
Human clinical research remains extremely limited
Monitoring and Safety Considerations Regular monitoring helps ensure safe and effective use of 5-amino-1MQ: Recommended Monitoring: Body weight and measurements (weekly) Energy levels and sleep quality (daily) Injection site assessment (each injection) Overall well-being and any unusual symptoms When to Seek Medical Attention: Persistent or severe side effects Unusual symptoms not resolving within 1-2 weeks Signs of allergic reaction (rash, difficulty breathing) Significant changes in heart rate or blood pressure Unexplained fatigue or weakness Long-Term Safety Considerations While short-term safety data for 5-amino-1MQ appears favorable, long-term safety in humans requires further study
The Class IIa includes HDACs 4,5, 7, and 9, while Class IIb includes HDAC 6 and 10
